Arizona State University/Halberd Corp. Outline Partnership 2nd Stage Goals of $1.4 M Covid-19 Program

Jackson Center, PA, September 17, 2020 – Halberd Corporation (OTC PINK: “HALB“) today outlined the specifics of the second stage goals of the $1.4 Million seven-phase research project with Arizona State University.

The second stage of the research involves an investigation of a method using dialysis, or a variant of dialysis, to remove the fluorescent antibody-antigen complex, for the rapid identification of a Covid-19 sample.

In an earlier press release, we enumerated the initial phase creation of a unique Covid-19 fluorescent antibody which may also contain an albumin moiety to facilitate the rapid identification of the Covid-19 target antigens.  The use of fluorescent antibody-antigen complex targets antigens for removal through our proprietary extracorporeal dialysis mechanism.

Work on the initial phase of the program is underway at ASU, with initial results expected within the next month. ASU has already identified some very promising initial findings.  Our technical team is following progress very closely. Dr. Patricio Reyes, Halberd’s Chief Technical Officer and Head of Neurology at the Phoenix VA, feels that these initial results may have more profound consequences and potential benefits than originally anticipated.  During a recent research coordination meeting, Dr. Reyes and Dr. Qiang Chen agreed that the use of convalescent serum could be invaluable in both the diagnosis and treatment of Covid-19.

William A. Hartman, Halberd Corporation Chairman, President & CEO, stated, “Dialysis is just one of the removal methods being investigated by Halberd/ASU.  Covid-19 is a very complex target antigen, and we are examining several methods of removal which we believe will result in an optimum treatment or combination of treatments designed to eradicate COVID-19 and other viral infections.  Other methods of our antibody-antigen removal techniques will be more fully explained in subsequent communications.”

The details of the Halberd-ASU research contract can be viewed here.

For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com
support@halberdcorporation.com
www.halberdcorporation.com
P. O. Box 25
Jackson Center, PA 16133
Twitter:@HalberdC

About Arizona State University.

Arizona State University is a public research university with 5 campuses in and around Phoenix, with four regional centers throughout Arizona.  It is one of the largest public universities, based on enrollment, and one of the fastest growing research universities in the United States. The school boasts over 400 National Academies-honored faculty, and 77 elite programs.

About Halberd Corporation.

Halberd Corporation. (OTC-PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. It is debt-free and holds the exclusive rights to the COVID-19 extracorporeal treatment technology provisional patent applications: “Method for Treating and Curing Covid-19 Infection;” “Method for Treating COVID-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in COVID-19 Patients;” and “Method for Treating and Curing COVID-19 Infection by Utilizing a Laser to Eradicate the Virus.”  Halberd also holds the exclusive rights to the underlying granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287.

Safe Harbor Notice
Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). The Companies caution that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance.  Forward-looking statements are based on estimates and opinions of management at the time statements are made.  These statements may address issues that involve significant risks, uncertainties, estimates made by management.  Actual results could differ materially from current projections or implied results. The Companies undertake no obligation to revise these statements following the date of this news release.

Investor caution/added risk for investors in companies claiming involvement in COVID-19 initiatives –

On April 8, 2020, SEC Chairman Jay Clayton and William Hinman, the Director of the Division of Corporation Finance, issued a joint public statement on the importance of disclosure during the COVID-19 crisis.

The SEC and Self-Regulatory Organizations are targeting public companies that claim to have products, treatment or other strategies with regard to COVID-19.

The ultimate impact of the COVID-19 pandemic on the Company’s operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak. Additionally, new information may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced customer traffic and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time.

We further caution investors that our primary focus and goal is to battle this pandemic for the good of the world. As such, it is possible that we may find it necessary to make disclosures which are consistent with that goal, but which may be adverse to the pecuniary interests of the Company and of its shareholders.